dextromethorphan extended release (FP-101) / Fervent Pharma - LARVOL DELTA

C-reactive protein and response to add-on dextromethorphan treatment in bipolar disorders: Results from a placebo-controlled trial (CINP-AsCNP 2025) - "The significant interaction between LogCRP and time on cognitive indices in this study highlights the potential role of inflammation in cognitive dysfunction in bipolar disorder. Elevated CRP levels, indicative of chronic low-grade inflammation, may contribute to deficits in key cognitive domains, including memory, attention, and executive function. These findings are consistent with previous research suggesting a link between inflammation and cognitive impairment in mood disorders.Moreover, the impact of valproic acid combined with dextromethorphan (VPA+DM) on these cognitive outcomes warrants further exploration."

Clinical • Alzheimer's Disease • Bipolar Disorder • CNS Disorders • Cognitive Disorders • Inflammation • Mood Disorders • Psychiatry • CRP

FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms (clinicaltrials.gov) - P2 | N=105 | Completed | Sponsor: Fervent Pharmaceuticals | Active, not recruiting ➔ Completed

Trial completion

FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms (clinicaltrials.gov) - P2 | N=105 | Active, not recruiting | Sponsor: Fervent Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed

FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: Fervent Pharmaceuticals | Trial completion date: Dec 2022 ➔ Sep 2023 | Trial primary completion date: Sep 2022 ➔ Jun 2023

Trial completion date • Trial primary completion date